India Glycols’ Big Split: Unlocking Value or Just Repackaging It?

$INDIAGLYCO India Glycols is moving through a major restructuring that may finally unlock value hidden inside the company. The NCLT has sanctioned its three-way split, and that is important because the market has long valued the business as one mixed basket instead of pricing each division separately. The company currently runs four businesses: Bio-based Specialities and Performance Chemicals, Potable Spirits, Bio-Fuel, and Ennature Bio. Under the approved plan, Potable Spirits and Bio-Fuel will be housed in IGL Spirits Limited, while the bio-pharma and bio-polymer business will go into Ennature Bio Pharma Limited. The remaining specialty chemicals business will stay with India Glycols. Shareholders will receive 1 share of IGL Spirits for every 1 share held, and 1 share of Ennature Bio Pharma for every 3 shares held. The logic is clear. Spirits is a higher-margin business, and separating it from chemicals can help investors value it more fairly. Today, the market values India Glycols as a blended entity at about ₹6,600 crore, around 22x earnings and 13x EV/EBITDA. That suggests the market may not yet be giving full credit to the better parts of the business. Recent numbers also look supportive. In Q4 FY26, the company reported revenue of ₹2,360 crore, EBITDA of ₹167.1 crore, and net profit of ₹86.9 crore, with profit up 35.7% year on year. These figures show that the underlying businesses are performing well enough for a cleaner structure to matter. For shareholders, this can be beneficial if the new companies get better valuation multiples and stronger analyst attention. The risk is that the value unlock may take time, and the market could apply discounts until the listing process is complete. Still, if execution is smooth, the split looks more value-creating than harmful.